MedTrace Logo

Diabetic Retinopathy in HIV Subjects Treated With EGRIFTA®

NCT01591902 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2018-09-11

No results posted yet for this study

Summary

To show the non-inferiority of EGRIFTA® vs. placebo in the development or progression of Diabetic Retinopathy in HIV-infected subjects with concomitant abdominal lipohypertrophy and Type 2 diabetes mellitus (T2DM).

Conditions

Interventions

DRUG

Tesamorelin

Daily 2 mg subcutaneous injections of tesamorelin

DRUG

Placebo-Control

3.0 mL vials

Sponsors & Collaborators

  • Theratechnologies

    lead INDUSTRY

Principal Investigators

  • Marilyn De Chantal

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-06-30
Primary Completion
2018-05-31
Completion
2018-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01591902 on ClinicalTrials.gov